Exelixis Inc Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Exelixis Inc (EXEL) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $36.34 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-07-03 was $36.34M, a 10.38% decline year-over-year.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-04-03 was $34.21M, a 52.00% increase year-over-year.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-01-02 was $4.81M, a 70.77% decline year-over-year.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-10-03 was $3.36M, a 55.26% increase year-over-year.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2026 was $71.23M, a 84.39% increase from fiscal 2025.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $38.63M, a 32.83% increase from fiscal 2023.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $29.08M, a 24.58% increase from fiscal 2022.
- Exelixis Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $23.34M, a 40.36% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-07-03 | $36.34M 10-Q · filed 2026-08-05 | $70.55M 10-Q · filed 2026-08-05 | $75.36M derived: sum of 3 quarters · filed 2026-08-05 | $78.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $34.21M 10-Q · filed 2026-05-05 | $39.02M derived: sum of 2 quarters · filed 2026-05-05 | $42.38M derived: sum of 3 quarters · filed 2026-05-05 | $82.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $8.17M derived: sum of 2 quarters · filed 2026-02-10 | $48.73M derived: sum of 3 quarters · filed 2026-08-05 | $71.23M 10-K · filed 2026-02-10 |
| 2025-10-03 | $3.36M 10-Q · filed 2025-11-04 | $43.92M derived: sum of 2 quarters · filed 2026-08-05 | $66.42M 10-Q · filed 2025-11-04 | $82.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $40.55M 10-Q · filed 2026-08-05 | $63.06M 10-Q · filed 2026-08-05 | $79.52M derived: sum of 3 quarters · filed 2026-08-05 | $81.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $22.51M 10-Q · filed 2026-05-05 | $38.96M derived: sum of 2 quarters · filed 2026-05-05 | $41.13M derived: sum of 3 quarters · filed 2026-05-05 | $54.14M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $18.62M derived: sum of 2 quarters · filed 2026-02-10 | $31.64M derived: sum of 3 quarters · filed 2026-02-10 | $38.63M 10-K · filed 2026-02-10 |
| 2024-09-27 | $2.17M 10-Q · filed 2025-11-04 | $15.18M derived: sum of 2 quarters · filed 2025-11-04 | $22.18M 10-Q · filed 2025-11-04 | $28.16M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $13.02M 10-Q · filed 2025-07-28 | $20.01M 10-Q · filed 2025-07-28 | $26.00M derived: sum of 3 quarters · filed 2026-02-10 | $35.75M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $6.99M 10-Q · filed 2025-05-13 | $12.98M derived: sum of 2 quarters · filed 2026-02-10 | $22.73M derived: sum of 3 quarters · filed 2026-02-10 | $33.55M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $15.74M derived: sum of 2 quarters · filed 2026-02-10 | $26.56M derived: sum of 3 quarters · filed 2026-02-10 | $29.08M 10-K · filed 2026-02-10 |
| 2023-09-29 | $9.75M 10-Q · filed 2024-10-29 | $20.57M derived: sum of 2 quarters · filed 2024-10-29 | $23.10M 10-Q · filed 2024-10-29 | $30.35M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $10.82M 10-Q · filed 2024-08-06 | $13.35M 10-Q · filed 2024-08-06 | $20.60M derived: sum of 3 quarters · filed 2025-02-11 | $25.50M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $2.52M 10-Q · filed 2024-04-30 | $9.78M derived: sum of 2 quarters · filed 2025-02-11 | $14.68M derived: sum of 3 quarters · filed 2025-02-11 | $20.91M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $12.16M derived: sum of 2 quarters · filed 2025-02-11 | $18.38M derived: sum of 3 quarters · filed 2025-02-11 | $23.34M 10-K · filed 2025-02-11 |
| 2022-09-30 | $4.91M 10-Q · filed 2023-11-01 | $11.13M derived: sum of 2 quarters · filed 2023-11-01 | $16.09M 10-Q · filed 2023-11-01 | $39.86M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $6.22M 10-Q · filed 2023-08-01 | $11.19M 10-Q · filed 2023-08-01 | $34.96M derived: sum of 3 quarters · filed 2024-02-06 | $40.91M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $4.96M 10-Q · filed 2023-05-09 | $28.73M derived: sum of 2 quarters · filed 2024-02-06 | $34.69M derived: sum of 3 quarters · filed 2024-02-06 | $37.46M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $23.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $29.73M derived: sum of 2 quarters · filed 2024-02-06 | $32.50M derived: sum of 3 quarters · filed 2024-02-06 | $39.14M 10-K · filed 2024-02-06 |
| 2021-10-01 | $5.96M 10-Q · filed 2022-11-01 | $8.72M derived: sum of 2 quarters · filed 2022-11-01 | $15.37M 10-Q · filed 2022-11-01 | $39.27M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $2.77M 10-Q · filed 2022-08-09 | $9.41M 10-Q · filed 2022-08-09 | $33.31M derived: sum of 3 quarters · filed 2023-02-07 | $38.49M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $6.65M 10-Q · filed 2022-05-10 | $30.54M derived: sum of 2 quarters · filed 2023-02-07 | $35.72M derived: sum of 3 quarters · filed 2023-02-07 | $54.87M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $29.08M derived: sum of 2 quarters · filed 2023-02-07 | $48.23M derived: sum of 3 quarters · filed 2023-02-07 | $50.02M 10-K · filed 2023-02-07 |
| 2020-10-02 | $5.18M 10-Q · filed 2021-11-02 | $24.33M derived: sum of 2 quarters · filed 2021-11-02 | $26.12M 10-Q · filed 2021-11-02 | $32.66M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $19.15M 10-Q · filed 2021-08-05 | $20.94M 10-Q · filed 2021-08-05 | $27.48M derived: sum of 3 quarters · filed 2022-02-18 | $28.41M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $1.79M 10-Q · filed 2021-05-06 | $8.33M derived: sum of 2 quarters · filed 2022-02-18 | $9.26M derived: sum of 3 quarters · filed 2022-02-18 | $10.12M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $7.47M derived: sum of 2 quarters · filed 2022-02-18 | $8.32M derived: sum of 3 quarters · filed 2022-02-18 | $9.90M 10-K · filed 2022-02-18 |
| 2019-09-27 | $935.00K 10-Q · filed 2020-11-05 | $1.79M derived: sum of 2 quarters · filed 2020-11-05 | $3.37M 10-Q · filed 2020-11-05 | |
| 2019-06-28 | $854.00K 10-Q · filed 2020-08-06 | $2.43M 10-Q · filed 2020-08-06 | ||
| 2018-12-28 | $7.57M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |